Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer

Anticancer Research

Volumn 35, Issue 4, 2015, Pages 2279-2285

  Ishigami, Sumiya ^a   Arigami, Takaaki ^a   Okumura, Hiroshi ^a   Uchikado, Yasuto ^a   Kita, Yoshiaki ^a   Kurahara, Hiroshi ^a   Maemura, Kosei ^a   Kijima, Yuko ^a   Ishihara, Yuka ^a   Sasaki, Ken ^a   Uenosono, Yoshikazu ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Gastric cancer; HLA E; HLA F; Immuno suppression; Postoperative outcome

Indexed keywords

HLA E ANTIGEN; HLA F ANTIGEN; HLA ANTIGEN CLASS 1; HLA-E ANTIGEN; HLA-F ANTIGENS;

ADULT; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CELL INVASION; CELL MEMBRANE; CONTROLLED STUDY; FEMALE; GASTRECTOMY; GASTRIC CANCER CELL LINE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION; AGED; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84928384439     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H and Sobue T: The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 38: 259-267, 2008.
2. Sasako M, Saka M, Fukagawa T, Katai H and Sano T: Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg 24: 101-107, 2004.
3. Kishimoto I, Mitomi H, Ohkura Y, Kanazawa H, Fukui N and Watanabe M: Abnormal expression of p16 (INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas. J Surg Oncol 98: 60-66, 2008.
4. Kamikihara T, Ishigami S, Arigami T, Matsumoto M, Okumura H, Uchikado Y, Kita Y, Kurahara H, Kijima Y, Ueno S and Natsugoe S: Clinical implications of N-cadherin expression in gastric cancer. Pathol Int 62: 161-166, 2012. Clinical implications of N-cadherin expression in gastric cancer. Pathol Int 62: 161-166, 2012.
5. Xiangming C, Natsugoe S, Takao S, Hokita S, Tanabe G, Baba M, Kuroshima K and Aikou T: The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer 89: 1214-1219, 2000.
6. Jang BG and Kim W: Molecular pathology of gastric carcinoma. Pathobiology 78: 302-310, 2011.
7. Tahara E: Genetic pathways of two types of gastric cancer. IARC Sci Publ 157: 327-349, 2004.
8. Kang JS, Bae SY, Kim HR, Kim YS, Kim DJ, Cho BJ, Yang HK, Hwang YI, Kim KJ, Park HS, Hwang DH, Cho DJ and Lee WJ: Interleukin-18 increases metastasis and immune escape of stomach cancer via the down-regulation of CD70 and maintenance of CD44. Carcinogenesis 30: 1987-1996, 2009.
9. Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K and Aikou T: HLA-class I expression in gastric cancer. J Surg Oncol 97: 605-608, 2008.
10. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Higashi H, Iwashige H, Aridome K, Hokita S and Aikou T: CD3-zeta chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 94: 1437-1442, 2002.
11. Arigami T, Uenosono Y, Hirata M, Yanagita S, Ishigami S and Natsugoe S: B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci 102: 1019-1024, 2011.
12. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet M and Geraghty DE: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 95: 5199-5204, 1998.
13. Bhalla A, Stone PR, Liddell HS, Zanderigo A and Chamley LW: Comparison of the expression of human leukocyte antigen (HLA)-G and HLA-E in women with normal pregnancy and those with recurrent miscarriage. Reproduction 131: 583-589, 2006.
14. Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H and Geraghty DE: Protein expression and peptide binding suggest unique and interacting functional roles for HLAE, F, and G in maternal-placental immune recognition. J Immunol 171: 1376-1384, 2003.
15. Shobu T, Sageshima N, Tokui H, Omura M, Saito K, Nagatsuka Y, Nakanishi M, Hayashi Y, Hatake K and Ishitani A: The surface expression of HLA-F on decidual trophoblasts increases from mid to term gestation. J Reprod Immunol 72: 18-32, 2006.
16. Spaans VM, Peters AA, Fleuren GJ and Jordanova ES: HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med 10: 184, 2012.
17. Benevolo M, Mottolese M, Tremante E, Rollo F, Diodoro MG, Ercolani C, Sperduti I, Lo Monaco E, Cosimelli M and Giacomini P: High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med 9: 184, 2011.
18. Lin A, Zhang X, Ruan YY, Wang Q, Zhou WJ and Yan WH: HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer 74: 504-509, 2011.
19. Kren L, Slaby O, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T, Fadrus P, Lakomy R, Vanhara P, Krenova Z, Sterba J, Smrcka M and Michalek J: Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: An unexpected prognostic significance? Neuropa tho logy 31: 129-134, 2011.
20. Szekeres-Bartho J: Immunological relationship between the mother and the fetus. Int Rev Immunol 21: 471-95, 2002.
21. Ishigami S, Natsugoe S, Miyazono F, Nakajo A, Tokuda K, Matsumoto M, Okumura H, Douchi T, Hokita S and Aikou T: HLA-G expression in gastric cancer. Anticancer Res 26(3B): 2467-2472, 2006.
22. Ishigami S, Arigami T, Setoyama T, Okumura H, Sasaki K, Uchikado Y, Kurahara H, Kijima Y, Nishizono Y, Nakajo A and Natsugoe S: Clinical-pathological implication of human leukocyte antigen-F-positive gastric adenocarcinoma. J Surg Res 184: 802-806, 2013.
23. Marín R, Ruiz-Cabello F, Pedrinaci S, Méndez R, Jiménez P, Geraghty DE and Garrido F: Analysis of HLA-E expression in human tumors. Immunogenetics 54: 767-75, 2003.
24. Sano T and Aikou T: New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer 14: 97-100, 2011.
25. rd English edition. Gastric Cancer 14: 101-112, 2011.
26. Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED and Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 64: 315-326, 2003.
27. Zhang J, Pan L, Chen L, Feng X, Zhou L and Zheng S: Nonclassical MHC-É genes in chronic hepatitis B and hepatocellular carcinoma. Immunogenetics 64: 251-258, 2012.
28. de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, Liefers GJ, van den Elsen PJ, van de Velde CJ and Kuppen PJ: HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 185: 7452-7459, 2010.
29. Pietra G, Romagnani C, Moretta L and Mingari MC: HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T-cells. Curr Pharm Des 15: 3336-3344, 2009.
30. Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG and Giacomini P: Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia 13: 822-830, 2011.
31. +Tlymphocytes. Proc Natl Acad Sci USA 108: 10656-10661, 2011.
32. Zhen ZJ, Ling JY, Cai Y, Luo WB and He YJ: Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med Oncol 30: 482, 2013.
33. Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M and Eisele G: HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol 250: 27-34, 2012.
34. Wei XH and Orr HT: Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol 29: 131-142, 1990.
35. Allard M, Oger R, Vignard V, Percier JM, Fregni G, Périer A, Caignard A, Charreau B, Bernardeau K, Khammari A, Dréno B and Gervois N: Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One 6: e21118, 2011.
36. Kren L, Valkovsky I, Dolezel J, Capak I, Pacik D, Poprach A, Lakomy R, Redova M, Fabian P, Krenova Z and Slaby O: HLAG and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma. Diagn Pathol 7: 58, 2012.
37. Enqvist M, Nilsonne G, Hammarfjord O, Wallin RP, Björkström NK, Björnstedt M, Hjerpe A, Ljunggren HG, Dobra K, Malmberg KJ and Carlsten M: Selenite induces postran scriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells. J Immunol 187: 3546-3554, 2011.